Neuropediatrics
DOI: 10.1055/s-0040-1718518
Original Article

The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

Katarína Česká
1  Department of Pediatric Neurology, Brno Epilepsy Center, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
,
Lukáš Český
2  Faculty of Electrical Engineering, Slovak University of Technology in Bratislava, Bratislava, Slovakia
,
Hana Ošlejšková
1  Department of Pediatric Neurology, Brno Epilepsy Center, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
,
Štefánia Aulická
1  Department of Pediatric Neurology, Brno Epilepsy Center, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
3  Ondrej Slaby Research Group, Central European Institute of Technology, Brno, Czech Republic
4  Department of Pediatric Oncology, University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
› Author Affiliations

Abstract

The objective of this study was to estimate the direct cost before and after diagnosis assessment in patients with Dravet's syndrome (DS). The basis of the economic study was to calculate the costs of health care before and after diagnosis of DS. We retrospectively evaluated all SCN1A positive patients with phenotype of DS treated in our hospital. Statistical analyses were performed by IBM SPSS Statistics 24.0 software. After the diagnosis of DS, there was a significant decline of health care costs (−85.6%) an average of €29.4 ± 26.1 monthly per patient. We estimated the monthly costs at €204.5 ± 167 (median: €193.9, range: €35.5–534.4) per patient before DS diagnosis. The major cost was for hospitalization in neurological department: €43.3 ± 52 (median: €21.9, range: €9.5–179.4) per patient. Minimal cost per patient per months before DS diagnosis was cost of psychological testing/care and complementary rehabilitation (0.13 and 0.6% of total cost). After DS diagnosis, the major cost was focused on nonhospitalization care of patients (64.8%), minimal (€0) for genetic testing and major for outpatient care (18%, mean: €5.3, median: €7). DS results in essential health care utilization and high financial burden before diagnosis elucidation caused by repeated hospitalization and extensive diagnostics tests of “epileptic encephalopathy of unknown etiology.” The results of this study point out that early assessment of the diagnosis leads to significant decrease of the financial costs because of adequate therapeutic management and exclusion of redundant diagnostic testing after elucidation of correct diagnosis.

Ethical Publication

We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.




Publication History

Received: 23 August 2019

Accepted: 12 July 2020

Publication Date:
13 October 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York